Quick navigation menu :

  1. Go to the content
  2. Go to the main sections menu
  3. Go to the search engine
  4. Go to the help menu
  5. Go to the modules
  6. Go to the shortcuts list

Help menu :

  1. Sanofi Worldwide |
     
  2. US Web Sites |
     
  3. Global Business Websites |
     
  4. Contact us |
  5. Sitemap |
  6. Help

  1. Font size

    Reduce font size Increase font size  
 

Press Releases

 
  1. Press Releases
  2. Press Statements
  3. SANOFI US PRESS KIT
  4. News Alerts
  5. Media Contacts
  6. Social Media
  7. Photos & Videos
 

Contact Us

Sanofi US
55 Corporate Drive
Bridgewater, NJ 08807





 

Our news releases are listed in chronological order and archived by year. To find news releases on a specific topic, utilize the search function.

Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008 / 2007 / 2006 / 2005

Category 

Jun 11, 2017
Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
- Data presented at the 77th Scientific Sessions of the American Diabetes Association (ADA) -
Jun 10, 2017
In Senior Adults Treated with Basal Insulin, Switching to Sanofi's Toujeo® Halved Hypoglycemia Risk
- New DELIVER 3 Real-World Toujeo® Observational Study Confirms Reduction of Hypoglycemia in Real-Life Setting -
Jun 10, 2017
New Analysis Shows Sanofi's Soliqua® 100/33 Lowered HbA1c by More Than 2 Percent in Patients with Screening Levels Greater than 9 Percent
- All subgroups treated with Soliqua 100/33 achieved a mean HbA1c of below 7 percent after 30 weeks -
Jun 4, 2017
Sanofi and Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting
- Oral presentation provides first REGN2810 data in patients with advanced cutaneous squamous cell carcinoma (CSCC) -
May 22, 2017
Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients
- Kevzara is now available to U.S. patients -
 

2017 News Releases

Share

Print Email page RSS
print email rss

Email information entered to email a page is only used to send the message and is not retained.

Corporate Information

Corporate Information